Literature DB >> 10190714

The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response.

J F Schlaak1, G Tully, H F Löhr, G Gerken, K H Meyer zum Büschenfelde.   

Abstract

BACKGROUND/AIMS: The aim of this study was to examine the influence of the viral load on costimulatory effects of rhIL-12 on the hepatitis B virus (HBV)-induced immune response.
METHODS: Peripheral blood mononuclear cells of HBsAg positive patients without cirrhosis were stimulated with HBsAg, HBcAg, preS1Ag and tetanus toxoid in the absence or presence of IL-12 (0.01, 0.1 and 1 ng/ml). Stimulation by alpha-CD3+alpha-CD28, pokeweed mitogen (PWM) and lipopolysaccharide (LPS) were used as controls. Then, proliferation and cytokine production were determined by 3H-thymidine uptake and ELISA after 72 h. The patients were divided into group 1 (n=21): HBV-DNA: not detectable, group 2 (n=13): HBV-DNA: <300 pg/ml, and group 3 (n= 10): HBV-DNA: >300 pg/ml.
RESULTS: After stimulation with only HBV antigens, the highest amounts of IL-10 were found in group 3, while interferon (IFN)-gamma was rarely detectable. After stimulation with IL-12 and HBV antigens, strong costimulatory effects on IFN-gamma production, as well as proliferation, were observed in all patients except individuals from group 3. With regard to antigen-unrelated stimulation, significantly lower amounts of LPS-induced IFN-gamma production and alpha-CD3+28 induced proliferative responses, but higher amounts of LPS-induced IL-10 were observed in group 3.
CONCLUSIONS: These data suggest that the presence of high amounts of HBV-DNA in serum is associated with suppressed co-stimulatory and regulatory effects of IL-12 on the immune response to HBV antigens. This may be one explanation for the poor response to immunostimulating therapy in patients with a high viral load.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10190714     DOI: 10.1016/s0168-8278(99)80090-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  13 in total

Review 1.  Memory CD8 T-cell differentiation during viral infection.

Authors:  E John Wherry; Rafi Ahmed
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 2.  Polyfunctional analysis of human t cell responses: importance in vaccine immunogenicity and natural infection.

Authors:  George Makedonas; Michael R Betts
Journal:  Springer Semin Immunopathol       Date:  2006-08-25

3.  Role of thymic output in regulating CD8 T-cell homeostasis during acute and chronic viral infection.

Authors:  Nicole E Miller; Jennifer R Bonczyk; Yumi Nakayama; M Suresh
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  Lamivudine. A review of its therapeutic potential in chronic hepatitis B.

Authors:  B Jarvis; D Faulds
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

5.  Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B - restoration by exogenous interleukin-12.

Authors:  H F Löhr; S Pingel; W O Böcher; H Bernhard; S Herzog-Hauff; S Rose-John; P R Galle
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

6.  Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment.

Authors:  E John Wherry; Joseph N Blattman; Kaja Murali-Krishna; Robbert van der Most; Rafi Ahmed
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence.

Authors:  María Cecilia Albareda; Gabriela Carina Olivera; Susana A Laucella; María Gabriela Alvarez; Esteban Rodrigo Fernandez; Bruno Lococo; Rodolfo Viotti; Rick L Tarleton; Miriam Postan
Journal:  J Immunol       Date:  2009-08-19       Impact factor: 5.422

8.  Impaired quality of the hepatitis B virus (HBV)-specific T-cell response in human immunodeficiency virus type 1-HBV coinfection.

Authors:  J Judy Chang; Sunee Sirivichayakul; Anchalee Avihingsanon; Alex J V Thompson; Peter Revill; David Iser; John Slavin; Supranee Buranapraditkun; Pip Marks; Gail Matthews; David A Cooper; Stephen J Kent; Paul U Cameron; Joe Sasadeusz; Paul Desmond; Stephen Locarnini; Gregory J Dore; Kiat Ruxrungtham; Sharon R Lewin
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

9.  Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections.

Authors:  Erik Depla; Annegret Van der Aa; Brian D Livingston; Claire Crimi; Koen Allosery; Veronique De Brabandere; Jonathan Krakover; Sidharta Murthy; Manley Huang; Scott Power; Lilia Babé; Carol Dahlberg; Denise McKinney; Alessandro Sette; Scott Southwood; Ramilla Philip; Mark J Newman; Lydie Meheus
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

10.  Treatment of chronic viral hepatitis in woodchucks by prolonged intrahepatic expression of interleukin-12.

Authors:  Julien Crettaz; Itziar Otano; Laura Ochoa-Callejero; Laura Ochoa; Alberto Benito; Astrid Paneda; Igor Aurrekoetxea; Pedro Berraondo; Juan Roberto Rodríguez-Madoz; Aurora Astudillo; Florian Kreppel; Stefan Kochanek; Juan Ruiz; Stephan Menne; Jesus Prieto; Gloria Gonzalez-Aseguinolaza
Journal:  J Virol       Date:  2008-12-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.